Drug news

NICE now recommends combination Farydak + Velcade (panobinostat + bortezomib+ dexamethasone) to treat multiple myeloma- Novartis

Read time: 1 mins

Last updated:5th Dec 2015

Published:5th Dec 2015

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) in a final appraisal now recommends Farydak + Velcade (panobinostat + bortezomib+ dexamethasone) from Novartis (subject to a discount) as third line treatment for patients with relapsed/refractory multiple myeloma who have received at least two prior therapies .

Comment:Patients receiving Farydak combination had a delay in their disease progression of about 7.8 months more than those given Velcade +dexamethasone alone.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 mins

Drug news

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose) in adults and adolescents (greater than 12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable

2 min

Drug news

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

1 min

See all news